The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

Investors

The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

Nov 8 - Nov 12, 2019

Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B

  • Publication Number: 0696
  • Session: Hepatitis B - Therapeutics: New Agents
  • Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Edward Gane, et al.

FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)

  • Publication Number: LP4
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Man-Fung Yuen, et al.

Location

Boston

Supporting Materials